A novel D-peptide modulates DCLK1 gelsolin interactions, reducing PDAC tumor growth
9.0
来源：
Nature
关键字：
computational biology
发布时间：
2025-10-15 00:00
摘要：
A novel D-peptide has been identified that targets the unique C-terminal region of DCLK1 isoforms 2 and 4, demonstrating significant inhibition of pancreatic ductal adenocarcinoma (PDAC) tumor growth in vitro and in vivo. This peptide modulates protein-protein interactions, enhancing the binding of pro-tumorigenic proteins, and suggests a new therapeutic avenue for PDAC treatment. The findings underscore DCLK1's role in cancer progression and highlight the potential for D-peptides in oncology, making it a promising candidate for early-stage investment.
原文：
查看原文
价值分投票
评分标准
新闻价值分采用0-10分制，综合考虑新闻的真实性、重要性、时效性、影响力等多个维度。
评分越高，表示该新闻的价值越大，越值得关注。
价值维度分析
domain_focus
1.0分+
business_impact
1.0分+
scientific_rigor
1.5分+
timeliness_innovation
1.5分+
investment_perspective
2.5分+
market_value_relevance
1.0分+
team_institution_background
0.5分+
technical_barrier_competition
1.0分+
关键证据
D-peptide 1 significantly suppressed PDAC cell proliferation and tumor growth in vivo.
D-peptide 1 binds DCLK1 isoform 4 with high affinity, indicating potential for therapeutic targeting.
The study highlights the role of DCLK1 in tumor progression and offers a novel approach to cancer treatment.
真实性检查
否
AI评分总结
A novel D-peptide has been identified that targets the unique C-terminal region of DCLK1 isoforms 2 and 4, demonstrating significant inhibition of pancreatic ductal adenocarcinoma (PDAC) tumor growth in vitro and in vivo. This peptide modulates protein-protein interactions, enhancing the binding of pro-tumorigenic proteins, and suggests a new therapeutic avenue for PDAC treatment. The findings underscore DCLK1's role in cancer progression and highlight the potential for D-peptides in oncology, making it a promising candidate for early-stage investment.